CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 5.44 USD -0.91% Market Closed
Market Cap: 1.2B USD

Operating Margin
CureVac NV

37.5%
Current
-314%
Average
-5%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
37.5%
=
Operating Profit
196.3m
/
Revenue
523.7m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
DE
CureVac NV
NASDAQ:CVAC
1.2B USD
37%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
327.3B USD
30%
US
Amgen Inc
NASDAQ:AMGN
155.6B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
135.1B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.3B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
116.3B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
55.2B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40.4B USD
-5%

CureVac NV
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
6.45 USD
Undervaluation 16%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

Summary
CVAC intrinsic value, competitors valuation, and company profile.
DCF Valuation
CVAC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CVAC stock valuation using valuation multiples.
Wall Street Estimates
CVAC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CVAC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
37.5%
=
Operating Profit
196.3m
/
Revenue
523.7m
What is the Operating Margin of CureVac NV?

Based on CureVac NV's most recent financial statements, the company has Operating Margin of 37.5%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 263,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.